Novartis’s third-quarter net income grew thanks to proceeds from its consumer health venture with GlaxoSmithKline, helping to offset declining revenue and heavy investment in its new heart-failure medicine and its ailing eye-care unit.
BASEL (dpa-AFX) - Novartis (NVS) reported third-quarter net income from
continuing operations of $1.9 billion, an increase of 7% year-over-year, up more
than operating income mainly due to higher income from associated companies. EPS
Novartis delivered solid third quarter with Growth Products offsetting
Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis International AG /
Novartis delivered solid third quarter with Growth Products...